StockData
Medicenna Therapeutics Corp. logo

Medicenna Therapeutics Corp. (MDNAF) shareholders

MDNAFOTCPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới năm tài chính 2023, năm kết thúc ngày Mar 31, 2023Last filing: 20-F on Jun 27, 2023
$0.28−0.02 (-7.63%)

Close on Oct 19, 2026

Ownership

Who owns Medicenna Therapeutics's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Rosemina Merchant
Joint filing with Fahar Merchant (29.10%), Aries Biologics Inc. (7.90%)
20,244,25529.10%13G (passive) amendmentDec 31, 2023
RA Capital Healthcare Fund, L.P.
Joint filing with RA Capital Management, L.P. (9.99%), Peter Kolchinsky (9.99%) and 1 more
7,714,7609.99%13G (passive)Apr 30, 2024
Orin Hirschman
Joint filing with AIGH Capital Management, LLC (6.60%)
4,672,0756.70%13G (passive) amendmentDec 31, 2023

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
1M shares short
Days to cover
7.0
At 0M shares a day
Change since last report
-4.8%
From 1M shares
Short volume, 0 days
–
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Medicenna Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 32,212 shares on Oct 7, 2026 over the last 90 days.

See a number that looks wrong?